Gemifloxacin

Summary

Gemifloxacin (CHEMBL430) is an approved small-molecule topoisomerase IV inhibitor (ATC J01MA15); indicated across 5 conditions including bacterial infectious disease and helicobacter pylori infectious disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01MA15
• Indications: 5 conditions
• Clinical trials: 4
• Chemistry: 389.4 Da · C18H20FN5O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL430
Name	Gemifloxacin
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	9571107
ChEBI	CHEBI:101853
ATC	J01MA15
Molecular formula	C18H20FN5O4
Molecular weight	389.4
InChIKey	ZRCVYEYHRGVLOC-HYARGMPZSA-N

SMILES: CO/N=C/1\CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F

IUPAC name: 7-[(4Z)-3-(aminomethyl)-4-methoxyiminopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid

ChEBI definition: A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.

Pharmacological roles (ChEBI): topoisomerase IV inhibitor, antimicrobial agent, antibacterial drug.

Also known as: Factiv, Gemifloxacin, Gemifloxacine, Gemifloxacino, gemifloxacin, GEMIFLOXACINE, GEMIFLOXACIN

Parent form; salt/anhydrous children: CHEMBL1200621

Patent coverage: 2,680 distinct patent families (9,759 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 9,723 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: D(1A) dopamine receptor, DNA gyrase, Muscarinic acetylcholine receptor M2, Dipeptidyl peptidase 4, DNA gyrase, DNA topoisomerase 4 subunit A.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 10 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P0C1U9	6.52	IC50	300	nM	CHEMBL_ACT_1695522
P0AES4	6.3	IC50	500	nM	CHEMBL_ACT_1695506
DPP4	5.57	IC50	2700	nM	CHEMBL_ACT_25050568
DRD1	5.44	AC50	3600	nM	CHEMBL_ACT_25234760
P0A0K8	5.25	IC50	5600	nM	CHEMBL_ACT_12070215
P0A0K8	5.25	IC50	5600	nM	CHEMBL_ACT_1804209
P0A0K8	5.25	IC50	5600	nM	CHEMBL_ACT_2348448
P0A0K8	5.25	IC50	5600	nM	CHEMBL_ACT_6184810

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
Helicobacter pylori infectious disease	3	MONDO:0006781	EFO:1000961
infectious peritonitis	3	MONDO:0004522	EFO:0008588
hypoglycemia	1	MONDO:0004946	HP:0001943

Clinical trials

Total trials: 4.

Phase distribution

Phase	Trials
PHASE4	1
PHASE3	1
EARLY_PHASE1	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00926796	PHASE4	COMPLETED	Efficacy of Combination Therapies for Gonorrhea Treatment
NCT04168099	PHASE3	RECRUITING	Oral Gemifloxacin Versus Intravenous Cefotaxime in Treatment of Spontaneous Bacterial Peritonitis
NCT04692623	PHASE1	COMPLETED	EFFECTS OF MOXIFLOXACIN AND GEMIFLOXACIN ON BLOOD GLUCOSE AND ECG MORPHOLOGY OF EUGLYCEMICS:A CLINICAL STUDY
NCT03326050	EARLY_PHASE1	UNKNOWN	Comparison Between Rifampicin and Gemifloxacin and Ciprofloxacin in Treatment of Rhinoscleroma

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).